CO152 Clinical Predictors of Axicabtagene Ciloleucel (AXI-CEL) Therapy for Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): A Systematic Literature Review (SLR) and Meta-Analysis
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.229
https://www.valueinhealthjournal.com/article/S1098-3015(22)02433-0/fulltext
Title :
CO152 Clinical Predictors of Axicabtagene Ciloleucel (AXI-CEL) Therapy for Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): A Systematic Literature Review (SLR) and Meta-Analysis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02433-0&doi=10.1016/j.jval.2022.09.229
First page :
Section Title :
Open access? :
No
Section Order :
11894